Abstract

As of March 31, 2021, Israel had administered 116 doses of vaccine for COVID-19 per 100 population (of any age) – far more than any other OECD country. It was also ahead of other OECD countries in terms of the share of the population that had received at least one vaccination (61%) and the share that had been fully vaccinated (55%). Among Israelis aged 16 and over, the comparable figures were 81 and 74%, respectively. In light of this, the objectives of this article are:To describe and analyze the vaccination uptake through the end of March 2021To identify behavioral and other barriers that likely affected desire or ability to be vaccinatedTo describe the efforts undertaken to overcome those barriersIsrael’s vaccination campaign was launched on December 20, and within 2.5 weeks, 20% of Israelis had received their first dose. Afterwards, the pace slowed. It took an additional 4 weeks to increase from 20 to 40% and yet another 6 weeks to increase from 40 to 60%. Initially, uptake was low among young adults, and two religious/cultural minority groups - ultra-Orthodox Jews and Israeli Arabs, but their uptake increased markedly over time.In the first quarter of 2021, Israel had to enhance access to the vaccine, address a moderate amount of vaccine hesitancy in its general population, and also address more intense pockets of vaccine hesitancy among young adults and religious/cultural minority groups. A continued high rate of infection during the months of February and March, despite broad vaccination coverage at the time, created confusion about vaccine effectiveness, which in turn contributed to vaccine hesitancy. Among Israeli Arabs, some residents of smaller villages encountered difficulties in reaching vaccination sites, and that also slowed the rate of vaccination.The challenges were addressed via a mix of messaging, incentives, extensions to the initial vaccine delivery system, and other measures. Many of the measures addressed the general population, while others were targeted at subgroups with below-average vaccination rates. Once the early adopters had been vaccinated, it took hard, creative work to increase population coverage from 40 to 60% and beyond.Significantly, some of the capacities and strategies that helped Israel address vaccine hesitancy and geographic access barriers are different from those that enabled it to procure, distribute and administer the vaccines. Some of these strategies are likely to be relevant to other countries as they progress from the challenges of securing an adequate vaccine supply and streamlining distribution to the challenge of encouraging vaccine uptake.

Highlights

  • As of the end of 2020, the State of Israel had administered almost 11.0 doses of vaccine per 100 population, while the highest rates were 3.5 in Bahrain and 1.4 in the United Kingdom

  • They can be divided into three major groups: long-standing characteristics of Israel that are extrinsic to health care, long-standing characteristics that are health-system specific, and more recent factors that are specific to the COVID-19 vaccination effort

  • Changes over time in the pace of vaccination When the vaccination program was launched in late December 2020, eligibility was restricted to persons aged 60 or over, nursing home residents, people at high risk due to serious medical conditions, and front-line health care workers [1]

Read more

Summary

Introduction

As of the end of 2020, the State of Israel had administered almost 11.0 doses of vaccine per 100 population (all ages), while the highest rates were 3.5 in Bahrain and 1.4 in the United Kingdom. All other countries had administered less than 1 dose per 100 population. They can be divided into three major groups: long-standing characteristics of Israel that are extrinsic to health care, long-standing characteristics that are health-system specific, and more recent factors that are specific to the COVID-19 vaccination effort. Long-standing characteristics of Israel that are extrinsic to health care

Objectives
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.